INSIGHTS & NEWS
May 2026
Shareholder Webinar
In this webinar, Léone Atayi (CEO) and Hadrien Lanvin (Deputy CEO) review the group’s transformation: completed financial restructuring. They present in detail the group’s three subsidiaries — Inoviem Scientific, a translational pharmacology CRO working directly on human tissues; PIMS Technology and its patient stratification instrument PIMS® Q8; B Cell Design and its patented antibodies for in vitro diagnostics — along with concrete targets for 2026: CE marking, first commercial orders and international expansion.